Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1651 • ACR Convergence 2023
Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Esther Vicente Rabaneda¹, Pedro Martínez-Fleta², Ana Triguero-Martínez², Emilia Roy³, Miren Uriarte-Ecenarro⁴, Francisco Gutiérrez-Rodríguez⁴, Patricia Quiroga⁴, Ana Romero⁴, Nuria Montes², Laura Esparcia Pinedo², María Aranzazu Alfranca², Rosario Garcia-Vicuna⁵, Francisco Sánchez-Madrid², Isidoro González-Álvaro⁴ and Santos Castañeda⁵, ¹Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ²Division of Immunology, Hospital Universitario de La Princesa, Madrid, Spain, ³Division of Internal Medicine, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain
Background/Purpose: Previous published works have raised the concern that methotrexate (MTX) might have a negative effect on immune response upon vaccine administration. At the beginning…
Abstract Number: 1728 • ACR Convergence 2023
A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis
Garth Blackler, James Akingbasote, Patti Kiser, Christopher Howlett, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada
Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…
Abstract Number: 1744 • ACR Convergence 2023
Histological and Molecular Comparison in the Synovial Tissue of Patients with Active Rheumatoid Arthritis to Remission
Selina Ohl¹, Klaus Frommer¹, Markus Rickert², Stefan Rehart³, Ulf Müller-Ladner¹ and Elena Neumann¹, ¹Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ²Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, ³Dept. of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease which leads to local and systemic manifestations. Subsequently, the inflamed synovium drives the destruction of…
Abstract Number: 1760 • ACR Convergence 2023
Methotrexate Augments the Release of Granulocyte-macrophage Colony-stimulating Factor from Activated Rheumatoid Arthritis Fibroblast-like Synoviocytes – Possible Consequences for Persistence of Joint Inflammation
Beatrice Bergström¹, Tilia Selldén¹, Miriam Bollmann², Mattias N.D Svensson¹ and Anna-Karin Hultgård Ekwall³, ¹University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³University of Gothenburg, Kullavik, Sweden
Background/Purpose: Activated fibroblast-like synoviocytes (FLS) are important mediators of synovitis and structural damage in rheumatoid arthritis (RA)[1]. Granulocyte-macrophage colony-stimulating factor (GM-CSF, encoded by the CSF2…
Abstract Number: 1815 • ACR Convergence 2023
The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Preeti Dhanasekaran¹, Margaret Ma², Manjari Lahiri², Li Wearn Koh³, Stanley Angkodjojo⁴, Andrew Yu Keat Khor⁵, James Jiaqi Liu⁶, Stephanie Wong⁷ and Siaw Ing Yeo⁶, ¹National University of Singapore, Singapore, Singapore, ²National University Hospital, Singapore, Singapore, ³Tan Tock Seng Hospital, Braddell Heights, Singapore, ⁴Sengkang General Hospital / Singhealth, Singapore, Singapore, ⁵Changi General Hospital, Singapore, Singapore, ⁶Singapore General Hospital, Singapore, Singapore, ⁷Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: To determine the association of body mass index (BMI) with incident COVID-19 infection in patients with inflammatory arthritis (IA) using biologic disease-modifying anti-rheumatic drugs…
Abstract Number: 1905 • ACR Convergence 2023
Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic
Rumey Ishizawar¹, Thuyvan Phan² and Steven Takacs³, ¹University of North Carolina at Chapel Hill, School of Medicine, Division of Rheumatology, Allergy, and Immunology, Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina Hospitals Department of Pharmacy, Apex, NC, ³University of North Carolina Faculty Physicians, Chapel Hill, NC
Background/Purpose: The 2021 American College of Rheumatology (ACR) guidelines for the treatment of rheumatoid arthritis (RA) recommend a treat-to-target approach to optimize clinical outcomes. This…
Abstract Number: 2097 • ACR Convergence 2023
Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque
Natalia Guajardo-Jauregui¹, Iris Colunga², José Ramón Azpiri-López², Dionicio A. Galarza-Delgado², Rosa Arvizu-Rivera³ and Jesus Alberto Cardenas-De la Garza⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Cardiovascular disease is the major cause of death in rheumatoid arthritis (RA) patients. Cardiovascular risk algorithms are employed to assess the likelihood of experiencing…
Abstract Number: 2114 • ACR Convergence 2023
The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function
Sho Fukui¹, Wolfgang Winkelmayer², Sara Tedeschi¹, Javier Marrugo¹, Hongshu Guan¹, Leslie Harrold³, Heather Litman³, Tomohiro Shinozaki⁴ and Daniel Solomon⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Baylor College of Medicine, Houston, TX, ³CorEvitas, LLC, Waltham, MA, ⁴Tokyo University of Science, Tokyo, Japan, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA) affecting 10-20% of patients. However, the influence of the longitudinal RA disease…
Abstract Number: 2130 • ACR Convergence 2023
Prevalence and Risk Factors of Pneumocystis Jirovecii Colonization in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors and Tocilizumab
Yi-Min Huang¹, Chieh-An Chuang², Jui-Hung Kao², Yen-Chun Lin², Jen-Hao Chen³, Chiao-Feng Cheng⁴, Cheng-Hsun Lu⁴, Yu-Min Kuo⁴, Chieh-Yu Shen⁴, Chin-Hsiu Liu⁵, Ko-Jen Li⁴, Song-Chou Hsieh⁴, Jung-Yien Chien⁴ and Po-Ren Hsueh⁴, ¹National Taiwan University Cancer Center, Taipei City, Taiwan, ²National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan, ³National Taiwan University Cancer Center, Taipei, Taiwan, ⁴National Taiwan University Hospital, Taipei, Taiwan, ⁵National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Patients with rheumatoid arthritis (RA) are susceptible toPneumocystis jiroveciicolonization and prone to develop life-threateningPneumocystispneumonia (PCP). An increased risk ofP. jiroveciicolonization and PCP was found…
Abstract Number: 2146 • ACR Convergence 2023
After JAK Inhibitor Failure, “Switching” or “Cycling”?
Pablo Francisco Muñoz Martínez¹, Laura Mas Sanchez², Elena Grau Garcia³, Carmen Riesco Barcena³, Anderson Victor Huaylla Quispe³, Alba Maria Torrat Noves³, Daniel Ramos Castro³, Belen Villanueva Mañez³, Iago Alcantara Alvarez³, Samuel Leal Rodriguez³, Elvira Vicens Bernabeu³, Jose Eloy Oller Rodriguez³, Ines Canovas Olmos³, Ernesto Tovar Sugrañes³, Carmen Najera Herranz³, Isabel Martinez Cordellat³, Hikmat Charia³, Rosa Negueroles Albuixech³, Marta De la Rubia Navarro², Luis Gonzalez Puig³, Jose Ivorra Cortes³ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Sagunto, Spain, ²Rheumatology Department. HUP La Fe, Valéncia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: The appearance of JAK inhibitors (JAKi) in the last few years has proved a great clinical application in rheumatic pathology and it has become…
Abstract Number: 2163 • ACR Convergence 2023
Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?
Joy van der Pol¹, Sytske Anne Bergstra², Thomas Huizinga² and CF Allaart², ¹Leiden University Medical Center, Utrecht, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The EULAR recommendations for the treatment of RA state, by expert opinion, that if a treatment target is not achieved with the first csDMARD…
Abstract Number: 2431 • ACR Convergence 2023
Integrated Single Cell Multi-omics Analysis in At-Risk for Future Rheumatoid Arthritis (RA) and Early RA Reveals Shared Transcription Factor Profiles in Multiple Cell Lineages
Cong Liu¹, David Boyle¹, Adam Savage², Marie Feser³, Kristen Demoruelle³, kristine Kuhn⁴, Michael Holer³, kevin Deane³, Palak Genge², Morgan Weiss², Veronica Hernandez², Julian Reading², Jane Buckner⁵, Tom Bumol², Mark Gillespie², Peter Skene², Wei Wang⁶ and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²Allen Institute for Immunology, Seattle, WA, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶University of California San Diego, La Jolla, CA
Background/Purpose: Identifying molecular signatures associated with anti-citrullinated protein antibody (ACPA) positive individuals who are 'at-risk' for future RA (At-Risk) and early RA (ERA) requires comprehensive…
Abstract Number: 2483 • ACR Convergence 2023
CD68 and Fibrinoid Necrosis Are Synovial Biomarkers of Severity in Early Rheumatoid Arthritis and Are Associated with a Better Response to Methotrexate: Analysis of the UCLouvain Brussels ERA Cohort
Francesco Natalucci¹, clement triaille², Emilie Sapart², Cécile VAN MULLEM², Tatiana Sokolova³, Laurent MERIC de BELLEFON², Adrien NZEUSSEU TOUKAP², Christine GALANT⁴, Bernard Lauwerys⁵ and Patrick Durez², ¹UCLouvain University, Sermoneta, Italy, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³Université Catholique de Louvain, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain), Anatomie pathologique, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with persistent synovial inflammation. Despite early diagnosis and the treatment-to-target strategy in ERA, the treatment response…
Abstract Number: 2584 • ACR Convergence 2023
Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis
Benoît Thomas P. GILBERT¹, Raul Yhossef TITO TADEO², Céline LAMACCHIA¹, Olivia STUDER¹, Delphine COURVOISIER¹, Jeroen RAES³ and Axel Finckh⁴, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium, ³Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven., Leuven, Belgium, ⁴HUG, Geneva, Switzerland
Background/Purpose: We attempted to replicate and expand previous findings of an increased abundance of Prevotellaceae in early untreated Rheumatoid Arthritis (RA) or its preclinical stages,…
Abstract Number: 0002 • ACR Convergence 2023
Population Pharmacokinetic and Pharmacodynamic Analyses of Obexelimab in Healthy Volunteers and in Patients with Rheumatoid Arthritis or IgG4-Related Diseases
Xiaodong Wang, Rachel Kirk, Simon Lowry and Hua Mu, Zenas BioPharma, Waltham, MA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefits across…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].